Reference Detail

Ref Type

PMID

Authors

Elisa A. Rozeman, Judith M. Versluis, Karolina Sikorska, Ruben Lacroix, Lindsay G Grijpink-Ongering, Birthe Heeres, Bart A. Van De Wiel, Petros Dimitriadis, Ayşegül Sari, Stijn Heijmink, Pia Kvistborg, Daan van den Broek, Annegien Broeks, Jan Willem de Groot, Sofie Wilgenhof, Marieke Anne Vollebergh, Johannes V. Van Thienen, John B. A. G. Haanen, Christian U. Blank

Title

The IMPemBra trial, a phase II study comparing pembrolizumab with intermittent/short‐term dual MAPK pathway inhibition plus pembrolizumab in melanoma patients harboring the BRAFV600 mutation.

Journal	Vol	Issue	Date	Pages	Journal Short Title

URL

https://meetinglibrary.asco.org/record/186980/abstract

Abstract Text

J Clin Oncol 38: 2020 (suppl; abstr 10021); DOI: 10.1200/JCO.2020.38.15_suppl.10021

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
BRAF V600K	melanoma	predicted - sensitive	Dabrafenib + Pembrolizumab + Trametinib	Phase II	Actionable	In a Phase II trial (IMPemBra), Keytruda (pembrolizumab) in combination with short-term or intermittent Tafinlar (dabrafenib) plus Mekinist (trametinib) resulted in improved median progression-free survival compared to Keytruda (pembrolizumab) monotherapy (27.0 vs 10.6 mo, p=0.13) in patients with treatment-naive advanced melanoma harboring BRAF V600E (n=26) or V600K (n=6) mutations (J Clin Oncol 38: 2020 (suppl; abstr 10021); NCT02625337).	detail...
BRAF V600E	melanoma	predicted - sensitive	Dabrafenib + Pembrolizumab + Trametinib	Phase II	Actionable	In a Phase II trial (IMPemBra), Keytruda (pembrolizumab) in combination with short-term or intermittent Tafinlar (dabrafenib) plus Mekinist (trametinib) resulted in improved median progression-free survival compared to Keytruda (pembrolizumab) monotherapy (27.0 vs 10.6 mo, p=0.13) in patients with treatment-naive advanced melanoma harboring BRAF V600E (n=26) or V600K (n=6) mutations (J Clin Oncol 38: 2020 (suppl; abstr 10021); NCT02625337).	detail...